Bristol-Myers Squibb Announces Opdivo Plus Low-Dose Yervoy Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer at ESMO 2018
Charles Gross